NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate CarcinomaInterventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging; Radiation: Fludeoxyglucose F-18; Radiation: Fluorine F 18 Sodium Fluoride; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission TomographySponsors: Stanford University; National Cancer Institute (NCI)Recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hormone Resistant Prostate Cancer | Hormones | MRI Scan | Prostate Cancer | Research